If you are interested in distributing Marinomed's OTC products, please contact our BD & L for more information.
Marinomed is further in contact with companies, which are interested in developing new virus-blocking products based on the Carragelose® platform. The platform can be used to extend or enhance existing therapies through the virus-blocking efficacy of Carragelose®. One of our examples is the decongestant combination, which received EU-wide certification in July 2018.
The Carragelose® platform can thus add value through new combinations by strengthening an existing product or a development portfolio.